Search

Your search keyword '"Lipworth, B.J."' showing total 163 results
Start Over Author "Lipworth, B.J."
163 results on '"Lipworth, B.J."'

4. The Effect of Inhaled Corticosteroid Withdrawal on the Airway Metagenome and Antimicrobial Resistance: Data From the INCOGNITO Trial

Author

Keir, H.R., primary, Narayana, J.K., additional, Richardson, H., additional, Xaverius, I., additional, Veluchamy, A., additional, Alferes de Lima, D., additional, Jaggi, T., additional, Hennayake, C., additional, Dicker, A., additional, Clarke, C., additional, Band, M., additional, Finch, S.M., additional, Billingham, P., additional, Crichton, M.L., additional, Bourke, S., additional, Haughney, J., additional, Lipworth, B.J., additional, Shaw, D., additional, Chotirmall, S.H., additional, and Chalmers, J.D., additional

Published
2023
Full Text
View/download PDF

7. The Effect of Inhaled Corticosteroid Withdrawal on Inflammation and the Airway Microbiome in COPD: The INCOGNITO Trial

Author

Keir, H.R., primary, Richardson, H., additional, Veluchamy, A., additional, Alferes de Lima, D., additional, Hennayake, C., additional, Cassidy, D., additional, Dicker, A.J., additional, Clarke, C., additional, Band, M., additional, Finch, S.M., additional, Billingham, P., additional, Crichton, M.L., additional, Bourke, S., additional, Haughney, J., additional, Lipworth, B.J., additional, Shaw, D., additional, and Chalmers, J.D., additional

Published
2022
Full Text
View/download PDF

9. Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma. (Original Article)

Author

Currie, G.P., Fowler, S.J., Wilson, A.M., Sims, E.J., Orr, L.C., and Lipworth, B.J.

Subjects
Care and treatment, Physiological aspects, Antiasthmatic agents -- Physiological aspects, Asthma -- Care and treatment
Abstract

Background: With the transition to hydrofluoroalkane-134a propellants in metered dose inhalers, it is important to consider the efficacy and safety profiles of formulations containing inhaled corticosteroids. We examined the airway [...]

Published
2002

15. Comparison of the effects of prolonged treatment with low and high doses of inhaled terbutaline on beta-adrenoceptor responsiveness in patients with chronic obstructive pulmonary disease

Author

Lipworth, B.J., Clark, R.A., Dhillon, D.P., and McDevitt, D.G.

Subjects
Terbutaline sulphate -- Dosage and administration, Adrenergic beta agonists -- Evaluation, Lung diseases, Obstructive -- Drug therapy, Health
Abstract

Chronic obstructive pulmonary disease (COPD) is characterized by an increased resistance to airflow within the lungs due to narrowing of the airways. This disorder is treated with inhaled beta-agonist drugs or oral doses of theophylline. Studies show that higher than usual doses of beta-agonist agents improve the airway response. However, higher doses can also cause systemic effects, including finger tremor; tachycardia, or rapid heart rate; hypokalemia, or abnormally low levels of potassium in the blood; and changes in the electrical activity of the heart. The effects of low and high doses of the beta-agonist terbutaline on the airways and on the system were assessed in 11 patients with COPD. Improvements in lung function were maintained after treatment with high dose but not the low dose. Potassium levels and heart rate were unaffected by either dose of terbutaline. Other systemic effects, such as finger tremor, changes in the electrical activity of the heart, and cyclic AMP levels were blunted after high-dose as compared with low-dose terbutaline. However, high doses of the beta-agonist caused the development of ventricular ectopy, or heart contractions abnormally originating within the heart ventricle. These abnormal beats did not develop into arrhythmias, or abnormal heart rhythms. The findings show that the effectiveness of terbutaline was maintained after treatment with high doses, which also blunted systemic effects to a greater extent than low doses of terbutaline. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1990

16. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis

Author

Bousquet, J. Schünemann, H.J. Hellings, P.W. Arnavielhe, S. Bachert, C. Bedbrook, A. Bergmann, K.-C. Bosnic-Anticevich, S. Brozek, J. Calderon, M. Canonica, G.W. Casale, T.B. Chavannes, N.H. Cox, L. Chrystyn, H. Cruz, A.A. Dahl, R. De Carlo, G. Demoly, P. Devillier, P. Dray, G. Fletcher, M. Fokkens, W.J. Fonseca, J. Gonzalez-Diaz, S.N. Grouse, L. Keil, T. Kuna, P. Larenas-Linnemann, D. Lodrup Carlsen, K.C. Meltzer, E.O. Mullol, J. Muraro, A. Naclerio, R.N. Palkonen, S. Papadopoulos, N.G. Passalacqua, G. Price, D. Ryan, D. Samolinski, B. Scadding, G.K. Sheikh, A. Spertini, F. Valiulis, A. Valovirta, E. Walker, S. Wickman, M. Yorgancioglu, A. Haahtela, T. Zuberbier, T. Aberer, W. Adachi, M. Agache, I. Akdis, C. Akdis, M. Annesi-Maesano, I. Ansotegui, I.J. Anto, J.M. Arshad, S.H. Baiardini, I. Baigenzhin, A.K. Barbara, C. Bateman, E.D. Beghé, B. Bel, E.H. Ben Kheder, A. Bennoor, K.S. Benson, M. Bernstein, D. Michael, B. Thomas, B. Bindslev-Jensen, C. Bjermer, L. Blain, H. Boner, A. Bonini, M. Bonini, S. Bosse, I. Bouchard, J. Boulet, L.-P. Bourret, R.A. Bousquet, P.J. Braido, F. Briggs, A.H. Brightling, C.E. Buhl, R. Burney, P. Bush, A. Caballero-Fonseca, F. Caimmi, D.P. Camargos, P. Camuzat, T. Carlsen, K.-H. Carr, W. Casale, T.B. Sarabia, A.C. Chatzi, L. Chen, Y. Chiron, R. Chkhartishvili, E. Chuchalin, A. Ciprandi, G. Cirule, I. Correia de Sousa, J. Costa, D. Crooks, G. Custovic, A. Dahlen, S.-E. Darsow, U. De Blay, F. De Manuel Keenoy, E. Dedeu, T. Deleanu, D. Denburg, J. Didier, A. Dinh-Xuan, A.-T. Dokic, D. Douagui, H.B. Dubakiene, R. Durham, S. Dykewicz, M. El-Gamal, Y. Emuzyte, R. Fink-Wagner, A. Fiocchi, A. Forastiere, F. Gamkrelidze, A. Gemicioğlu, B. Gereda, J.E. Gerth van Wijk, R. Gotua, M. Grisle, I. Guzmán, M.A. Haahtela, T. Heinrich, J. Hellquist-Dahl, B. Horak, F. Howarth, P.H. Humbert, M. Hyland, M. Ivancevich, J.-C. Jares, E.J. Johnston, S.L. Jonquet, O. Joos, G. Jung, K.-S. Just, J. Jutel, M. Kaidashev, I.P. Khaitov, M. Kalayci, O. Kalyoncu, F. Keith, P. Khaltaev, N. Kleine-Tebbe, J. Klimek, L. N'Goran, B.K. Kolek, V. Koppelman, G.H. Kowalski, M. Kull, I. Kvedariene, V. Lambrecht, B. Lau, S. Laune, D. Le Thi Tuyet, L. Li, J. Lieberman, P. Lipworth, B.J. Renaud, L. Magard, Y. Magnan, A. Mahboub, B. Majer, I. Makela, M. Manning, P.J. Masjedi, M.R. Maurer, M. Mavale-Manuel, S. Melén, E. Melo-Gomes, E. Mercier, J. Merk, H. Miculinic, N. Mihaltan, F. Milenkovic, B. Mohammad, Y. Molimard, M. Momas, I. Montilla-Santana, A. Morais-Almeida, M. Mösges, R. Nadif, R. Namazova-Baranova, L. Neffen, H. Nekam, K. Neou, A. Niggemann, B. Nyembue, D. O'Hehir, R. Ohta, K. Okamoto, Y. Okubo, K. Ouedraogo, S. Paggiaro, P.-L. Pali-Schöll, I. Palmer, S. Panzner, P. Papi, A. Park, H.-S. Pavord, I. Pawankar, R. Pfaar, O. Picard, R. Pigearias, B. Pin, I. Plavec, D. Pohl, W. Popov, T. Postma, D.S. Potter, P. Poulsen, L.K. Rabe, K.F. Raciborski, F. Pontal, F.R. Reitamo, S. Repka-Ramirez, M.-S. Robalo-Cordeiro, C. Roberts, G. Rodenas, F. Rolland, C. Rodriguez, M.R. Romano, A. Rosado-Pinto, J. Rosario, N.A. Rosenwasser, L. Rottem, M. Sanchez-Borges, M. Sastre-Dominguez, J. Schmid-Grendelmeier, P. Serrano, E. Simons, F.E.R. Sisul, J.-C. Skrindo, I. Smit, H.A. Solé, D. Sooronbaev, T. Spranger, O. Stelmach, R. Strandberg, T. Sunyer, J. Thijs, C. Todo-Bom, A.-M. Triggiani, M. Valenta, R. Valero, A.L. van Hage, M. Vandenplas, O. Vezzani, G. Vichyanond, P. Viegi, G. Wagenmann, M. Wahn, U. De Yun, W. Williams, D. Wright, J. Yawn, B.P. Yiallouros, P. Yusuf, O.M. Zar, H.J. Zernotti, M. Zhang, L. Zhong, N. Zidarn, M.

Abstract

The selection of pharmacotherapy for patients with allergic rhinitis (AR) depends on several factors, including age, prominent symptoms, symptom severity, control of AR, patient preferences, and cost. Allergen exposure and the resulting symptoms vary, and treatment adjustment is required. Clinical decision support systems (CDSSs) might be beneficial for the assessment of disease control. CDSSs should be based on the best evidence and algorithms to aid patients and health care professionals to jointly determine treatment and its step-up or step-down strategy depending on AR control. Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR [fighting chronic diseases for active and healthy ageing]), one of the reference sites of the European Innovation Partnership on Active and Healthy Ageing, has initiated an allergy sentinel network (the MACVIA-ARIA Sentinel Network). A CDSS is currently being developed to optimize AR control. An algorithm developed by consensus is presented in this article. This algorithm should be confirmed by appropriate trials. © 2016 The Authors

Published
2016

17. Respiratory effect of beta-blocker eye drops in asthma: population-based study and meta-analysis of clinical trials

Author

Morales, D.R, Dreischulte, T, Lipworth, B.J, Donnan, P.T, Jackson, Catherine, Guthrie, B, Morales, D.R, Dreischulte, T, Lipworth, B.J, Donnan, P.T, Jackson, Catherine, and Guthrie, B

Abstract

Aims: To measure the prevalence of beta-blocker eye drop prescribing and respiratory effect of ocular beta-blocker administration in people with asthma. Methods: We measured the prevalence of ocular beta-blocker prescribing in people with asthma and ocular hypertension, and performed a nested case–control study (NCCS) measuring risk of moderate exacerbations (rescue steroids in primary care) and severe exacerbations (asthma hospitalization) using linked data from the UK Clinical Practice Research Datalink. We then performed a systematic review and meta-analysis of clinical trials evaluating changes in lung function following ocular beta-blocker administration in people with asthma. Results: From 2000 to 2012, the prevalence of non-selective and selective beta-blocker eye drop prescribing in people with asthma and ocular hypertension fell from 23.0% to 13.4% and from 10.5% to 0.9% respectively. In the NCCS, the relative incidence (IRR) of moderate exacerbations increased significantly with acute non-selective beta-blocker eye drop exposure (IRR 4.83, 95% CI 1.56–14.94) but not with chronic exposure. In the meta-analysis, acute non-selective beta-blocker eye drop exposure caused significant mean falls in FEV1 of −10.9% (95% CI −14.9 to −6.9), and falls in FEV1 of ≥20% affecting one in three. Corresponding values for selective beta-blockers in people sensitive to ocular non-selective beta-blockers was −6.3% (95% CI −11.7 to −0.8), and a non-significant increase in falls in FEV1 of ≥20%. Conclusion: Non-selective beta-blocker eye drops significantly affect lung function and increase asthma morbidity but are still frequently prescribed to people with asthma and ocular hypertension despite safer agents being available.

Published
2016

50. β2-agonists in asthma

Author

Palmer, J.B.D, primary, Jenkins, M.M, additional, Dahl, Ronald, additional, Crompton, GrahamK, additional, Crane, Julian, additional, Burgess, Carl, additional, Beasley, Richard, additional, Pearce, Neil, additional, Clark, T.J.H, additional, Lipworth, B.J, additional, Newnham, D, additional, Mcdevitt, D.G, additional, O'Shaughnessy, KevinM, additional, Taylor, IanK, additional, Fuller, RichardW, additional, Twentyman, O.P, additional, Finnerty, J.P, additional, Rogers, Trevor, additional, Higgins, Katharine, additional, and Morice, Alyn, additional

Published
1991
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results